Profound MedicalPROF -1.02%73 FCF Margin % is -160.82% as of Mar. 2026. GuruFocus rates PROF with a GF Score™ of 73/100 and a GF Value™ of $14.28 (Possible Value Trap). The stock has 1 warning sign investors should review. Among 817 Medical Devices & Instruments companies, Profound Medical ranks worse than 88.62% on this metric.
The historical rank and industry rank for Profound Medical's FCF Margin % or its related term are showing as below:
PROF'
s FCF Margin % Range Over the Past 10 Years
Min: -702.76 Med: -314.06 Max: -204.67
Current: -204.67
During the past 12 years, the highest FCF Margin % of Profound Medical was -204.67%. The lowest was -702.76%. And the median was -314.06%.
PROF's FCF Margin % is ranked worse than 88.62% of 817
companies
in the Medical Devices & Instruments industry
Industry Median: -0.34
vs PROF: -204.67
Profound Medical FCF Margin % Related Terms
Profound Medical FCF Margin % Historical Data
* Premium members only.
The historical data trend for Profound Medical's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Profound Medical's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Profound Medical FCF Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Profound Medical's FCF Margin % distribution charts can be found below:
* The bar in red indicates where Profound Medical's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Profound Medical (PROF) has a FCF Margin % of -160.82% as of Mar. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Profound Medical and its competitors. According to the industry distribution chart, Profound Medical ranks #724 out of 817 companies in the Medical Devices & Instruments industry, placing it in the top 88.6%.
Is Profound Medical's FCF Margin % too high?
Profound Medical's current FCF Margin % is -160.82%. Based on the distribution chart, Profound Medical ranks #724 out of 817 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Profound Medical has a GF Score™ of 73/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Profound Medical's FCF Margin % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Profound Medical ranks #724 out of 817 companies for FCF Margin %. This places Profound Medical in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Medical Devices & Instruments company?
A good FCF Margin % depends on the Medical Devices & Instruments industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Profound Medical and its competitors. Profound Medical's current FCF Margin % is -160.82%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Profound Medical stock overvalued right now?
Based on GuruFocus' analysis, Profound Medical (PROF) is currently considered Possible Value Trap. The stock's GF Value™ is $14.28, compared to a current price of $7.26 — trading 49.2% below its estimated fair value. The current FCF Margin % is -160.82%. Profound Medical's overall GF Score™ is 73/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Profound Medical (PROF), the current FCF Margin % is -160.82% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Profound Medical (PROF) Overvalued in 2026?
Based on GuruFocus' analysis, Profound Medical stock appears to be undervalued.
The current stock price of $7.26 is trading 49.2% below its estimated GF Value™ of $14.28.
GuruFocus considers Profound Medical to be Possible Value Trap.
Key valuation signals for PROF:
FCF Margin %: -160.82%
GF Value™: $14.28 vs. price of $7.26 (49.2% below fair value)
No single metric tells the full story. See the PROF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Profound Medical Corp is a commercial-stage medical device company focused on the development and marketing of AI-powered, MRI-guided, incision-free therapies for the ablation of diseased tissue. The company's flagship product, the TULSA-PRO system, combines real-time MRI, robotically-driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to ablate whole gland or physician defined region of malignant or benign prostate tissue. Its platform technologies combine imaging, robotic control, and ultrasound-based thermal ablation for the treatment of prostate conditions. The company generates revenue through the sale of capital equipment and recurring sales of single-use devices and related services used in patient treatments.
73GF Score
Get the complete analysis for PROF
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PROF has been successfully added to your 
